Veru Inc. (NASDAQ: VERU) reported its financial results for the quarter ended March 31, 2020, on Wednesday before the market opens. The company posted a narrower loss for Q2 as the substantial growth in prescription sales of FC2 drove the top-line higher.
On Tuesday, Veru received FDA permission to initiate a phase 2 clinical trial to assess the efficacy of VERU-111 in combating COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2. Veru has initiated the study and expects the first patient to be dosed within 2 weeks.
The company believes that VERU-111, a microtubule depolymerization agent that has broad antiviral activity, could be effective against the SARS CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to cause infection.
Past Performance
Most Popular
KMI Earnings: Kinder Morgan reports financial results for Q3 2024
Energy infrastructure company Kinder Morgan, Inc. (NYSE: KMI) on Wednesday reported financial results for the third quarter of 2024. Net income, adjusted for special items, remained unchanged year-over-year at $0.25
Earnings Preview: General Motors’ Q3 results likely to benefit from EV growth
General Motors Co. (NYSE: GM) is expected to report its third-quarter results on October 22. The company is working towards the goal of achieving operating profit in its rapidly growing
What to expect when Philip Morris (PM) reports Q3 2024 earnings results
Shares of Philip Morris International Inc. (NYSE: PM) stayed green on Wednesday. The stock has gained 11% over the past three months. The tobacco giant is scheduled to report its
